404 related articles for article (PubMed ID: 11944917)
1. Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.
Okada M; Tokumitsu H; Kubota Y; Kobayashi R
Biochem Biophys Res Commun; 2002 Apr; 292(4):1023-30. PubMed ID: 11944917
[TBL] [Abstract][Full Text] [Related]
2. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family.
Shishibori T; Oyama Y; Matsushita O; Yamashita K; Furuichi H; Okabe A; Maeta H; Hata Y; Kobayashi R
Biochem J; 1999 Mar; 338 ( Pt 3)(Pt 3):583-9. PubMed ID: 10051426
[TBL] [Abstract][Full Text] [Related]
3. Two distinct anti-allergic drugs, amlexanox and cromolyn, bind to the same kinds of calcium binding proteins, except calmodulin, in bovine lung extract.
Oyama Y; Shishibori T; Yamashita K; Naya T; Nakagiri S; Maeta H; Kobayashi R
Biochem Biophys Res Commun; 1997 Nov; 240(2):341-7. PubMed ID: 9388479
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox.
Okada M; Itoh H; Hatakeyama T; Tokumitsu H; Kobayashi R
Biochem J; 2003 Sep; 374(Pt 2):433-41. PubMed ID: 12803546
[TBL] [Abstract][Full Text] [Related]
5. Purification of bovine S100A12 from recombinant Escherichia coli.
Yamashita K; Oyama Y; Shishibori T; Matsushita O; Okabe A; Kobayashi R
Protein Expr Purif; 1999 Jun; 16(1):47-52. PubMed ID: 10336859
[TBL] [Abstract][Full Text] [Related]
6. Molecular level interactions of S100A13 with amlexanox: inhibitor for formation of the multiprotein complex in the nonclassical pathway of acidic fibroblast growth factor.
Rani SG; Mohan SK; Yu C
Biochemistry; 2010 Mar; 49(11):2585-92. PubMed ID: 20178375
[TBL] [Abstract][Full Text] [Related]
7. Heterodimeric interaction and interfaces of S100A1 and S100P.
Wang G; Zhang S; Fernig DG; Spiller D; Martin-Fernandez M; Zhang H; Ding Y; Rao Z; Rudland PS; Barraclough R
Biochem J; 2004 Aug; 382(Pt 1):375-83. PubMed ID: 15171681
[TBL] [Abstract][Full Text] [Related]
8. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.
Kishimoto K; Kaneko S; Ohmori K; Tamura T; Hasegawa K
Mediators Inflamm; 2006; 2006(1):42726. PubMed ID: 16864903
[TBL] [Abstract][Full Text] [Related]
9. Identification of effector binding sites on S100 beta: studies with guanylate cyclase and p80, a retinal phosphoprotein.
Pozdnyakov N; Margulis A; Sitaramayya A
Biochemistry; 1998 Jul; 37(30):10701-8. PubMed ID: 9692960
[TBL] [Abstract][Full Text] [Related]
10. A structural basis for S100 protein specificity derived from comparative analysis of apo and Ca(2+)-calcyclin.
Mäler L; Sastry M; Chazin WJ
J Mol Biol; 2002 Mar; 317(2):279-90. PubMed ID: 11902843
[TBL] [Abstract][Full Text] [Related]
11. Hydrophobic residues in the C-terminal region of S100A1 are essential for target protein binding but not for dimerization.
Osterloh D; Ivanenkov VV; Gerke V
Cell Calcium; 1998 Aug; 24(2):137-51. PubMed ID: 9803314
[TBL] [Abstract][Full Text] [Related]
12. Affinity of S100A1 protein for calcium increases dramatically upon glutathionylation.
Goch G; Vdovenko S; Kozłowska H; Bierzyñski A
FEBS J; 2005 May; 272(10):2557-65. PubMed ID: 15885104
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Ca2+ and Cu2+ requirements of the FGF1-S100A13 interaction measured by quartz crystal microbalance: an initial step in amlexanox-reversible non-classical release of FGF1.
Matsunaga H; Ueda H
Neurochem Int; 2008 May; 52(6):1076-85. PubMed ID: 18164517
[TBL] [Abstract][Full Text] [Related]
14. S100A1 utilizes different mechanisms for interacting with calcium-dependent and calcium-independent target proteins.
Landar A; Rustandi RR; Weber DJ; Zimmer DB
Biochemistry; 1998 Dec; 37(50):17429-38. PubMed ID: 9860858
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of S100 homodimerization and heterodimeric interactions by the yeast two-hybrid system.
Deloulme JC; Gentil BJ; Baudier J
Microsc Res Tech; 2003 Apr; 60(6):560-8. PubMed ID: 12645004
[TBL] [Abstract][Full Text] [Related]
16. Fragment docking to S100 proteins reveals a wide diversity of weak interaction sites.
Arendt Y; Bhaumik A; Del Conte R; Luchinat C; Mori M; Porcu M
ChemMedChem; 2007 Nov; 2(11):1648-54. PubMed ID: 17705319
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional characterization of retinal calcium-dependent guanylate cyclase activator protein (CD-GCAP): identity with S100beta protein.
Pozdnyakov N; Goraczniak R; Margulis A; Duda T; Sharma RK; Yoshida A; Sitaramayya A
Biochemistry; 1997 Nov; 36(46):14159-66. PubMed ID: 9369488
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of S100-target protein interactions.
Zimmer DB; Wright Sadosky P; Weber DJ
Microsc Res Tech; 2003 Apr; 60(6):552-9. PubMed ID: 12645003
[TBL] [Abstract][Full Text] [Related]
19. Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta, -eta and -zeta) in a rat model of cerebral basilar artery vasospasm.
Lefranc F; Decaestecker C; Brotchi J; Heizmann CW; Dewitte O; Kiss R; Mijatovic T
Neuropathol Appl Neurobiol; 2005 Dec; 31(6):649-60. PubMed ID: 16281914
[TBL] [Abstract][Full Text] [Related]
20. Ca(2+) binding protein S100A1 competes with calmodulin and PIP2 for binding site on the C-terminus of the TPRV1 receptor.
Grycova L; Holendova B; Lansky Z; Bumba L; Jirku M; Bousova K; Teisinger J
ACS Chem Neurosci; 2015 Mar; 6(3):386-92. PubMed ID: 25543978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
